NCT06483295 Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
| NCT ID | NCT06483295 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Chest Hospital |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 216 participants |
| Start Date | 2024-03-24 |
| Primary Completion | 2024-07-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 216 participants in total. It began in 2024-03-24 with a primary completion date of 2024-07-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study focuses on the significant impact of lung cancer in China, highlighted by its high incidence and mortality rates, influenced by factors like aging populations, smoking, and environmental issues. It emphasizes the importance of understanding the duration, severity, and factors affecting post-surgery symptoms like pain and coughing in patients. The research underlines the value of patient-reported outcomes (PROs) in enhancing postoperative care and survival rates through improved symptom monitoring and patient engagement. Utilizing internet technology, specifically a platform integrated with WeChat, the study aims to improve patient management and follow-ups post-discharge. The objective is to use mobile internet technology to build a high-quality prospective database on postoperative lung cancer patient outcomes, analyzing factors affecting postoperative discomfort and assessing the role of interactive platforms in improving patient care.
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with Stage I-III lung cancer and surgically resected at our centre. 2. Owns and uses a smartphone and can use WeChat. 3. Volunteer to participate in this study and sign an informed consent form. Exclusion Criteria: 1. Received any non-surgical anti-tumour therapy (radiotherapy, chemotherapy, targeted therapy or immunotherapy) for lung cancer during the follow-up period. 2. After enrolment, preoperative emergence of serious comorbidities (inability to tolerate surgery or anaesthesia) that are not suitable for, or cannot be implemented as planned, in the study's treatment regimen. 3. After admission, the patient's condition changes and the need to change from elective surgery to emergency surgery is confirmed by the doctor in charge. 4. At any stage after entering the study, the patient voluntarily requests to withdraw or discontinue treatment due to personal reasons.
Contact & Investigator
Xinghua Cheng, MD
PRINCIPAL INVESTIGATOR
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Frequently Asked Questions
Who can join the NCT06483295 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06483295 currently recruiting?
Yes, NCT06483295 is actively recruiting participants. Contact the research team at chengxinghua_001@163.com for enrollment information.
Where is the NCT06483295 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06483295 clinical trial?
NCT06483295 is sponsored by Shanghai Chest Hospital. The principal investigator is Xinghua Cheng, MD at Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.. The trial plans to enroll 216 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.